Skip to main content
Contact Us
Subscribe
E-Edition
87°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Fulgent Genetics Inc
(NQ:
FLGT
)
23.80
+0.75 (+3.25%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fulgent Genetics Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Fulgent Reports Second Quarter 2024 Financial Results
August 02, 2024
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
July 11, 2024
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
June 03, 2024
From
Fulgent Pharma
Via
Business Wire
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
May 24, 2024
From
Fulgent Pharma
Via
Business Wire
Earnings Preview: Fulgent Genetics
November 02, 2023
Via
Benzinga
Why Is Fulgent Genetics Stock Moving Higher Today?
August 04, 2023
Fulgent Genetics Inc (NASDAQ: FLGT) reported Q2 sales of $68 million, beating the consensus estimate of $62.68 million.<
Via
Benzinga
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
May 14, 2024
From
Fulgent Pharma
Via
Business Wire
FLGT Stock Earnings: Fulgent Genetics Beats EPS, Misses Revenue for Q1 2024
May 03, 2024
FLGT stock results show that Fulgent Genetics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Fulgent Reports First Quarter 2024 Financial Results
May 03, 2024
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
April 11, 2024
From
Fulgent Genetics, Inc.
Via
Business Wire
Earnings Outlook For Fulgent Genetics
August 03, 2023
Via
Benzinga
Fulgent Genetics Earnings Perspective: Return On Capital Employed
May 19, 2023
Via
Benzinga
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024
February 13, 2024
From
Fulgent Genetics, Inc.
Via
Business Wire
The 3 Best Digital Health Stocks for Personalized Medicine
November 25, 2023
Digital health stocks are becoming increasingly relevant as more and more people seek greater control over their health.
Via
InvestorPlace
Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference
November 14, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting
November 03, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
Earnings Scheduled For November 3, 2023
November 03, 2023
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.
Via
Benzinga
Fulgent Reports Third Quarter 2023 Financial Results
November 03, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting
October 25, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023
October 17, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
September 29, 2023
Via
Benzinga
Fulgent Reports Second Quarter 2023 Financial Results
August 04, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
Earnings Scheduled For August 4, 2023
August 04, 2023
Companies Reporting Before The Bell • WPP (NYSE:WPP) is projected to report earnings for its first quarter. • Anglogold Ashanti (NYSE:AU) is likely to report earnings for its first quarter.
Via
Benzinga
Exagen Inc. Appoints Paul Kim to Board of Directors
July 24, 2023
From
Exagen Inc.
Via
GlobeNewswire
Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023
July 18, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
Got $2,500? This Dirt Cheap Growth Stock Could Be Worth Buying Hand Over Fist
June 06, 2023
Fulgent is moving past its pandemic-era business, and that's a good thing.
Via
The Motley Fool
Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers
June 05, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics
May 23, 2023
Neither has a traditional business model, but that could be an asset for both.
Via
The Motley Fool
2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years
May 23, 2023
Both are experiencing a bit of a hangover from declining COVID-19-related sales.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.